In Vitro and In Silico Inhibitory Activity Study of Polyphenols on Acetylcholinesterase
Keywords:
docking, molecular dynamics, acetylcholinesterase, inhibitors, polyphenolsAbstract
Introduction: Dysfunction and loss of cholinergic neurons in the central nervous system are among the earliest events in the pathogenesis of Alzheimer's disease. Acetylcholinesterase inhibition can alleviate dementia symptoms in Alzheimer's disease. Galantamine is an approved acetylcholinesterase inhibitor used for symptomatic treatment of the disease.
Aim: To investigate the binding affinities of six polyphenols (gallic, ellagic, caffeic and p-coumaric acids, catechin and epicatechin) for acetylcholinesterase using molecular docking and molecular dynamics simulations, compare them with galantamine, and determine their IC50 values.
Materials and Methods: Molecular docking was performed using AutoDock, and the highest-ranked conformation was selected as the initial complex for a 100 ns molecular dynamics simulation in GROMACS. RMSD, RMSF, hydrogen bonds and binding free energy estimated using MM/PBSA were analyzed. IC50 values were determined in triplicate by UV–Vis spectrophotometry using 5,5′-dithiobis(2-nitrobenzoic acid) as the indicator (λ = 412 nm).
Results: Catechin, epicatechin, ellagic acid and p-coumaric acid formed hydrogen bonds in the acetylcholinesterase active site during docking. During the 100 ns molecular dynamics simulations, all four compounds remained in the active site, with estimated ΔG values < 0 kcal/mol, whereas caffeic and gallic acids left the active site. IC50 values for catechin, epicatechin, p-coumaric acid and ellagic acid were 0.017 ± 0.0003 mg/mL, 0.04 ± 0.01 mg/mL, 0.145 ± 0.012 mg/mL and 0.163 ± 0.011 mg/mL, respectively. Gallic and caffeic acids showed no inhibitory activity within the tested concentration range. None of the compounds showed greater activity than galantamine.
Conclusion: Catechin, epicatechin, ellagic acid and p-coumaric acid inhibited acetylcholinesterase, although less potently than galantamine. Nevertheless, these compounds may serve as promising starting scaffolds for further investigation and structural modification toward derivatives with improved inhibitory activity.